Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl M Gay

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Biorxiv : the Preprint Server for Biology|December 25, 2025
CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized levelMukulika Bose, Cole Ruoff, Shafqat Ehsan, et al.
Cancer Cell|September 12, 2023
Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsiesZsolt Megyesfalvi, Simon Heeke, Benjamin J Drapkin, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerBenjamin B Morris, Simon Heeke, Yuanxin Xi, et al.
Molecular Cancer|March 21, 2025
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerBenjamin B Morris, Simon Heeke, Yuanxin Xi, et al.
Oncotarget|February 18, 2017
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancerC Allison Stewart, Pan Tong, Robert J Cardnell, et al.
Ebiomedicine|March 16, 2024
Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancerSehhoon Park, Tae Hee Hong, Soohyun Hwang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2024
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2023
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposideStephen V Liu, Tony S K Mok, Barzin Y Nabet, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
YAP1 defines an emergent, plastic population of relapsed small cell lung cancerC Allison Stewart, Kavya Ramkumar, Runsheng Wang, et al.
JCO Precision Oncology|October 30, 2025
Multi-Institution Analysis of Tarlatamab for the Treatment of <i>EGFR</i>-Mutant Transformed Small Cell Lung CancerAlissa J Cooper, Benjamin Herzberg, Mitchell Parma, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Biorxiv : the Preprint Server for Biology|December 25, 2025
CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized levelMukulika Bose, Cole Ruoff, Shafqat Ehsan, et al.
Cancer Cell|September 12, 2023
Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsiesZsolt Megyesfalvi, Simon Heeke, Benjamin J Drapkin, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerBenjamin B Morris, Simon Heeke, Yuanxin Xi, et al.
Molecular Cancer|March 21, 2025
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerBenjamin B Morris, Simon Heeke, Yuanxin Xi, et al.
Oncotarget|February 18, 2017
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancerC Allison Stewart, Pan Tong, Robert J Cardnell, et al.
Ebiomedicine|March 16, 2024
Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancerSehhoon Park, Tae Hee Hong, Soohyun Hwang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2024
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2023
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposideStephen V Liu, Tony S K Mok, Barzin Y Nabet, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
YAP1 defines an emergent, plastic population of relapsed small cell lung cancerC Allison Stewart, Kavya Ramkumar, Runsheng Wang, et al.
JCO Precision Oncology|October 30, 2025
Multi-Institution Analysis of Tarlatamab for the Treatment of <i>EGFR</i>-Mutant Transformed Small Cell Lung CancerAlissa J Cooper, Benjamin Herzberg, Mitchell Parma, et al.
Pageof 8